Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. Chen L, Lu Z, Zhang X, Lai J, et al. PLoS One 2025;20:e0332421.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Chen L, Lu Z, Zhang X, Lai J, et al. Risk of hepatitis B virus reactivation in the treatment of HBsAg and HBV DNA double-negative lymphoma patients. PLoS One 2025;20:e0332421.
PMID: 40961165